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We thank Dr. Macbeth for his comments on our article,
“Survival Outcomes in Asymptomatic Patients with Normal
Conventional Imaging (CI) but Raised Carcinoembryonic
Antigen Levels (CEA) in Colorectal Cancer Following Posi-
tron Emission Tomography-Computed Tomography Imaging
(PET-CT),” which has been recently published in this journal
[1]. The points raised emphasize the challenges encoun-
tered in interpretation of data from meta-analyses contain-
ing heterogeneous results. Indeed, the author himself in
the study by Mokhles et al. demonstrated no signiﬁcant over-
all survival (OS) advantage in 16 selected randomized clinical
trials of primary surveillance for colorectal cancer (CRC)
patients [2].
Firstly, we acknowledge the limitations linked to data
interpretation in cohort observational studies and prefera-
bly the need for a randomized clinical trial in order to pro-
vide sufﬁcient evidence to inﬂuence clinical practice.
However, conducting a randomized clinical trial to validate
the approach of secondary surveillance in this unique
cohort of high-risk patients is a signiﬁcant undertaking; the
logistical and ethical barriers in a comparative study requir-
ing patients to be randomized to PET-CT versus no PET-CT
arms in the presence of raised CEA levels need to be taken
into account. Notwithstanding the potential biases of a ret-
rospective study, we report a large cohort of 1,200 consec-
utive and unselected patients on CRC follow-up in a
tertiary referral center that indeed minimizes the selection
bias. Moreover, the last patient recruited in our study was
in 2010, which allowed at least a 5-year follow up of the
recruited cohort, thereby minimizing for the immortal time
bias [3].
Another issue raised by the author in his response is that
of “metastatic disease being considered as systemic rather
than a localized problem.” Although we agree that this conven-
tional concept is true for most solid cancers, we respectfully
disagree that the same concept is universally true for meta-
static CRC patients. There are sufﬁcient data that oligo-
metastatic disease amenable to localized treatment options
can be treated with radical intent in selected relapsed CRC
patients, and in fact long-term remission can be achieved in up
to 40% of such patients [4]. In our cohort, 27 of 49 (55%)
patients with PET-CT–detected relapsed disease were eligible
for further radical therapy, 19 (70%) of these patients went on
to receive radical therapy, and 36.8% were proven to be long-
term survivors.
In the current economic environment, we acknowledge
the need for appraisal of cost-effectiveness of therapeutic or
screening approaches in cancer management. Although a
detailed quality-adjusted life-year (QALY) analysis was beyond
the scope of this study, it is notable that in this large cohort,
very few patients (88/1,200 [7.3%]) underwent a PET-CT scan.
We do not suggest that PET-CT is used in unselected patients.
The cost of a PET-CT at approximately £800 is twice that of a
contrast-enhanced computed tomography (CT; £400) and
more expensive than magnetic resonance imaging (MRI;
£600). In National Institute for Health and Care Excellence
(NICE) guidance on CRC, two studies were included in the cost-
efﬁcacy analysis of intensive versus conventional follow-up
protocols. Both of these were interpreted as showing intensive
follow-up to be cost-effective; Renehan et al. calculated a cost
of £3,402 per life-year gained [5], and McAfee et al. calculated
an additional cost of £15.4 million to detect an additional 853
resectable recurrences, equating to £18,077 per additional
resectable recurrence [6]. Neither of these analyses
included trials that included PET-CT within the intensive
follow-up arm, and it is therefore difﬁcult to relate the
additional expense of PET-CT to these analyses. However,
French and American studies have demonstrated PET-CT to
be a cost-effective method of staging patients with liver
metastases prior to radical surgery, largely by avoiding
unnecessary surgery on patients found to have occult met-
astatic disease [7]. In patients found to have an isolated
extrahepatic metastasis on other imaging modalities, PET-
CT is recommended by NICE prior to considering radical
treatment. In patients with isolated hepatic metastasis on
CT, the most cost-effective sequence in which to perform
MRI and PET-CT is not clear, and NICE has recommended
further research evaluation. Of note, the majority of PET-
CT–detected relapses eligible for radical treatment in our
series were patients with recurrences conﬁned to the liver
or pelvis, amenable to radical treatment usually in the form
of surgery. Given that PET-CT provides whole body imaging,
whereas MRI does not allow detection of distant relapse
such as lung metastases, it would seem more logical and
cost-effective to sequence PET-CT as the initial investiga-
tion, reserving MRI only for cases in which it is clinically
required for further evaluation.
Finally, a simple analysis of cost-efﬁcacy would be to look
at the additional cost of performing PET-CT over CT alone on
100 patients with an elevated CEA and normal CI. Extrapolat-
ing the results from this series, 63 of these patients would be
expected to have relapsed disease, of which 55 would be
expected to be detected by PET-CT. Fifty-ﬁve percent of these
would be eligible for radical treatment of the relapse, translat-
ing to 30 patients. Performing a PET-CT on 100 patients would
cost an additional £80,000, equating to a cost of £2,666 per
patient treated potentially with radical intent on recurrence.
This is oversimpliﬁed because the majority of patients treated
with radical intent at recurrence will require further imaging
such as MRI, and this does not take into account the relative
treatment costs of both curative and palliative treatment.
However, in the context of life-years extended free of disease,
this far surpasses the QALY that is associated with NICE
approval for end of life care (30 kilo).
In summary, we would like to take this opportunity to once
again advise caution when interpreting the results of our study
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and the unnecessary use of PET-CT; however, this investigation
should be conducted in carefully selected patients who may
achieve long-term disease control, if found to be eligible for
localized treatment options.
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